Zonisamide effective for weight loss in women

Kim, Caroline S.
August 2003
Journal of Family Practice;Aug2003, Vol. 52 Issue 8, p600
Academic Journal
The article discusses research on the efficacy of zonisamide drug for weight loss in women. This drug is also used for treating people with epilepsy. Conducted to assess weight loss in sixty obese adults, the study was implemented in two phases. The zonisamide group lost significantly more weight than the placebo group in the initial phase of the clinical trial. Also reported were the zonisamide group's improvements in health, work, mobility and activities of daily living. Commentators of this research said that zonisamide was well-tolerated in obese female patients.


Related Articles

  • Regression From Pre-Diabetes to Normal Glucose Regulation in the Diabetes Prevention Program. Perreault, Leigh; Kahn, Steven E.; Christophi, Costas A.; Knowler, William C.; Hamman, Richard F. // Diabetes Care;Sep2009, Vol. 32 Issue 9, p1583 

    OBJECTIVE -- Participants in the Diabetes Prevention Program (DPP) randomized to intensive lifestyle modification (ILS) or metformin had a significantly reduced incidence of diabetes compared with those randomized to placebo, yet most were still at risk because they had pre-diabetes. We explored...

  • Ephedra and ephedrine: Modest short-term weight loss, with a price. Worley, Carl; Lindbloom, Erik // Journal of Family Practice;Jul2003, Vol. 52 Issue 7, p518 

    Products containing ephedrine and ephedra promote a 0.6-1.0 kg/mo weight loss over 2 to 6 months. However, the impact of these products on long-term weight loss or athletic performance is uncertain. Their use is associated with a 2- to 3-fold higher rate of psychiatric symptoms, autonomic...

  • Clinical Evaluation of the Anorexic Activity and Safety of 42-548 in Children. Sharma, R. K.; Collipp, P. J.; Rezvani, I.; Strimas, J.; Maddaiah, V. T.; Rezvani, E. // Clinical Pediatrics;Mar1973, Vol. 12 Issue 3, p145 

    A double-blind study comparing the safety and efficacy of 42-548, a new, synthetic tricyclic appetite suppressant, with a placebo was started with 116 obese adolescent patients. All patients received a fixed daily dose of one tablet, one hour before the noon meal, for 12 weeks. A reduced caloric...

  • Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity. Smith, Steve R.; Aronne, Louis J.; Burns, Colleen M.; Kesty, Nicole C.; Halseth, Amy E.; Weyer, Christian // Diabetes Care;Sep2008, Vol. 31 Issue 9, p1816 

    OBJECTIVE -- To assess long-term weight loss efficacy and safety of pramlintide used at different dosing regimens and in conjunction with lifestyle intervention (LSI). RESEARCH DESIGN AND METHODS-- In a 4-month, double-blind, placebo-controlled, dose-ranging study, 411 obese subjects were...

  • Effect of milnacipran on body weight in patients with fibromyalgia. Arnold, Lesley M.; Palmer, Robert H.; Hufford, Michael R.; Wei Chen // International Journal of General Medicine;2012 Part 2, Vol. 5, p879 

    Background: The purpose of this study was to evaluate the effects of milnacipran on body weight in patients with fibromyalgia. Methods: Analyses were conducted in the following groups: patients from three double-blind, placebo-controlled milnacipran trials (3 months, n = 2096; 6 months, n =...

  • Review: orlistat and sibutramine are modestly effective for weight loss at 1 year. R., Padwal; Li S.K.; Lou D.C. // Evidence Based Medicine;Feb2005, Vol. 10 Issue 1, p13 

    The article reports that orlistat and sibutramine are modestly effective for weight loss at 1 year. Only trials of orlistat and sibutramine met the selection criteria. 16 Random Clinical Trials (RCTs) (11 of orlistat and 5 of sibutramine) were included. 14 RCTs (11 of orlistat and 3 of...

  • Sustained Weight Loss Following 1-y Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity. Smith, Steven; Klein, Eric; Burns, Colleen; Kesty, Nicole; Halseth, Amy; Weyer, Christian // Diabetes;Jun2007 Supplement 1, Vol. 56, pA88 

    In a previously reported 4 mo, randomized, placebo-controlled, dose-ranging study, treatment with the amylin analog pramlintide (120, 240, 360 µg, BID/TID) used in conjunction with lifestyle intervention (LSI) resulted in additional weight loss than observed with LSI alone. To assess the...

  • Practical NLP: Negotiating Being Fat. Blake, Nancy // Positive Health;May2009, Issue 158, p1 

    The article addresses the health dangers and other issues of being fat, particularly in women. The author shared her weight loss story after her surgical operation at age 14. According to her, several factors have been attributed to being fat such as genetics, variations in the way people...

  • Effects of Weight Status and Barriers on Physical Activity Adoption Among Previously Inactive Women. Napolitano, Melissa A.; Papandonatos, George D.; Borradaile, Kelley E.; Whiteley, Jessica A.; Marcus, Bess H. // Obesity (19307381);Nov2011, Vol. 19 Issue 11, p2183 

    This study examined self-reported physical activity (PA) barriers, and their effects on PA behavior change at 3 and 12 months among 280 previously inactive women enrolled in a PA promotion trial. Effect modification of baseline barriers by baseline weight status on PA behavior change was also...


Other Topics